Dendrobium, PEA Supplements Carry Risks For Manufacturers
This article was originally published in The Tan Sheet
Executive Summary
FDA warns against using dendrobium and phenethylamines in dietary supplements, but firms that move forward anyways should do so “with eyes wide open” and conduct extra identity, safety and quality assurance tests, CRN’s MacKay advises.
You may also be interested in...
Ingredient Safety Concerns Rise Among FDA Enforcement Priorities
Ingredient safety, new dietary ingredient notifications, adverse event reporting, claims substantiation and disease claims are all drawing FDA attention in the supplement space, Daniel Fabricant says. Compliance for good manufacturing practices still heads the priorities for enforcement, he says.
DMAA Is Synthetic And Needs NDI Notification – Study
Botanical experts refute that DMAA is a geranium plant derivative and that the ingredient has been common in the food supply, as some supplement manufacturers have argued. “Elementary mathematics establishes that [DMAA] in dietary supplements must be synthetic,” study authors say.
DMAA Warnings Shed Light On FDA NDI Enforcement
FDA’s warning letters to 10 marketers of DMAA-containing products might have a silver lining for the supplement industry as they suggest the agency may be flexible on its controversial interpretation of some provisions in the new dietary ingredient notification requirement.